Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015

Ardine M.J. Reedijk, Jan Willem W. Coebergh, Hester A. de Groot-Kruseman, Inge M. van der Sluis, Leontien C. Kremer, Henrike E. Karim-Kos*, Rob Pieters

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

26 Citations (Scopus)
18 Downloads (Pure)


We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age group and ALL subtype. Between 1990 and 2015, 2997 ALL patients were diagnosed, i.e. 115 patients (range 87–147) per year. Overall incidence remained stable at 37 per million children, despite increases for B-cell precursor ALL (BCP-ALL) at age 10–14 years (AAPC + 1.4%, p = 0.04) and T-cell ALL at 15–17 years (AAPC + 3.7%, p = 0.01). Five-year survival increased from 80% in 1990–94 to 91% in 2010–15 (p < 0.01). Mortality decreased by 4% annually (p < 0.01). Patients 15–17 years were increasingly treated in a paediatric oncology centre, from 35% in 1990–94 to 87% in 2010–15 and experienced a 70% reduction of risk of death compared to those treated outside such a centre (p < 0.01). Significant progress against childhood ALL has been made in the Netherlands, visible by improved survival rates coinciding with declining mortality rates. These outcomes were accompanied by stable incidence rates, despite increases for BCP-ALL at age 10–14 years and T-cell ALL at age 15–17 years.

Original languageEnglish
Pages (from-to)1001-1011
Number of pages11
Issue number4
Publication statusPublished - Apr 2021

Bibliographical note

The current work is funded by Stichting Kinderen Kankervrij (KiKa) [project number 207]. The funding source had no role in the study design, data collection, analyses and interpretation of the results, nor in writing of this manuscript. We thank the registration team of the Netherlands Comprehensive Cancer Organization (IKNL) for the collection of data for the Netherlands Cancer Registry. We thank Dr. Otto Visser (IKNL) for the extra data checks for the current study. We thank the laboratory personnel and the data managers from the Dutch Childhood Oncology Group (DCOG) for collecting the data for the DCOG registry. We recognise all paediatric oncologists who treated the patients and provided data in the DCLSG/DCOG collaboration.

Publisher Copyright: © 2020, The Author(s).


Dive into the research topics of 'Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015'. Together they form a unique fingerprint.

Cite this